Hydrochlorothiazide reduces urinary calcium excretion in a child with Lowe syndrome. by Butani, Lavjay
UC Davis
UC Davis Previously Published Works
Title
Hydrochlorothiazide reduces urinary calcium excretion in a child with Lowe syndrome.
Permalink
https://escholarship.org/uc/item/8d49x6st
Journal
Clinical Kidney Journal, 8(4)
ISSN
2048-8505
Author
Butani, Lavjay
Publication Date
2015-08-01
DOI
10.1093/ckj/sfv048
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
EXC E PT I ONA L CAS E
Hydrochlorothiazide reduces urinary calcium excretion
in a child with Lowe syndrome
Lavjay Butani
Section of Pediatric Nephrology, University of California Davis Medical Center, Sacramento, CA, USA
Correspondence to: Lavjay Butani; E-mail: lavjay.butani@ucdmc.ucdavis.edu
Abstract
There is a growing recognition that children with Lowe syndrome are at risk of nephrocalcinosis and nephrolithiasis from
hypercalciuria. Increased fluid intake and correction ofmetabolic acidosis have remained the focus for intervention but are not
always successful. Thiazide diuretics, which reduce urinary calcium excretion, have not been used in these children, due to
concerns that (i) they may not work as a result of the underlying tubular abnormalities and (ii) their risk may outweigh the
potential benefits they have to offer. Herein we report a child with Lowe syndromewhowas successfully treated with thiazides
in managing his hypercalciuria.
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Background
The oculocerebrorenal syndrome of Lowe (Lowe syndrome) is a
rare multisystem X-linked disorder resulting from mutations in
the gene coding for an inositol 5-phosphatase, OCRL1 [1]. Clinical
manifestations include ocular abnormalities (congenital catar-
acts, buphthalmos and nystagmus), neurologic symptoms (devel-
opmental delay, aggressive behavior, seizures andmyopathy) and
renal involvement. The renal involvement of Lowe syndrome is
progressive and characterized by a proximal tubulopathy leading
to Fanconi’s syndrome [2]. Treatment of this is supportive and in-
volves correction of acidosis and supplementation of fluid and
electrolytes such as potassium and phosphorous. Over time, in
most patients glomerular filtration rate (GFR) declines in a slow
and progressive manner, although some patients demonstrate a
bi-phasic pattern of GFR decline; the mechanism of loss of renal
function remains unclear [2]. Patients with Fanconi’s syndrome
have generally been thought to be at a lower risk of stone forma-
tion and nephrocalcinosis in spite of having hypercalciuria (com-
pared with those with distal renal tubular acidosis) due to their
very dilute urine and elevated urinary citrate excretion [3].
However, there are some reports of children with Lowe syndrome
developing nephrocalcinosis, in spite of correction of their acid-
osis [4, 5]. There are limited data on the use of thiazide diuretics
in these children as a means to treating their hypercalciuria and
preventing progression of nephrocalcinosis; moreover, concern
has been raised regarding the safety and efficacy of using amedi-
cation that could further affect tubular function and lead to
worsening electrolyte and fluid balance.
Herein we are reporting our experience in managing a child
with Lowe syndrome who developed nephrolithiasis as a result
of hypercalciuria and who was successfully managed with thia-
zide diuretics.
Case description
An 11-year-old boy with Lowe syndrome, followed in the pediat-
ric nephrology practice since the age of 7.5 years, was brought in
for the evaluation of a 1-week history of intermittent gross pain-
less hematuria (bright red urine). Hewas otherwise asymptomat-
ic; although his verbal communication skills were delayed, he did
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not appear in pain. His medications included 250 mg daily of
phosphorous and 5 mEq/kg daily of oral potassium citrate; he
had been on a stable dose of both medications for 18 months
prior to his hematuria. He was polydispic and polyuric, as ex-
pected, and had nocturnal enuresis, precluding precise quantita-
tion of his urine output. His fluid intake was estimated by his
mother to be around 3 liters a day. His electrolytes, when he
presented with hematuria, were normal and notable for serum
potassium of 3.6 mmol/L (3.6 mEq/L), bicarbonate of 26 mmol/L
(mEq/L), total calcium of 2.5 mmol/L (9.9 mg/dL), phosphorus of
1.2 mmol/L (3.9 mg/dL) and uric acid of 181.4 µmol/L (3.3 mg/dL).
His estimated GFR (eGFR), based on the Schwartz calculation
[6], was 1.37 mL/s/1.73 m2 (82 mL/min/1.73 m2); relevant urine
studies included a urine pH of 8.0, an elevated random urine cal-
cium/creatinine ratio (UCa/Cr) of 2.8 mmol/mmol (1.0 mg/mg,
normal in children above the age of 7 years and in adults is
<0.22 mg/mg) and a markedly elevated urinary citrate excretion
at 2291 mg/g creatinine. His parathyroid hormone level, mea-
sured 9 months earlier, was 27 (normal 10–65) pg/mL; all subse-
quent values remained normal until after his eGFR declined.
Vitamin D levels were not obtained at this time. The first vitamin
D measurements were 1 year after presentation and were 62
(normal 15–75) pg/mL for 1,25-Vitamin D and 64 (normal 20–57)
ng/mL for 25-Vitamin D. An abdominal radiograph and subse-
quent CT scan showed multiple bilateral radio-opaque stones,
the largest being at the right ureteropelvic junction. The abdom-
inal radiographwas the initial modality chosen, as opposed to an
ultrasound, based on it being the most readily accessible in a
rapid manner in our outpatient setting. Once the stones were
noted on the radiograph, a CT scan was performed to confirm
the number, size and location of the stones, in preparation for
lithotripsy. For this, he underwent extra corporeal shock wave
lithotripsy, initially for the right-sided stones and 4 months
later for the left-sided calculi. A follow-up abdominal radiograph
showed small bilateral lower pole residual calculi; a decision was
made to follow these conservatively with no intervention. At last
follow-up, 9 years after the first diagnosis of renal stones, this
young man remains asymptomatic with stable stone burden.
Due to his hypercalciuria, he was started on hydrochlorothia-
zide (HCTZ) immediately after the stones were first detected. The
HCTZ dosewas progressively increased and amiloridewas added
to prevent and treat his hypokalemia. Over time, his phosphor-
ous supplementation also needed to be increased to 375 mg
daily. At last follow-up, he was receiving 5 mg once daily of
amiloride (0.125 mg/kg/day) and 1.3 mg/kg/day of HCTZ. No epi-
sodes of volume depletion or worsening electrolyte abnormality
were noted, with the exception of transient hypokalemia that im-
proved once amiloridewas added and on an increased potassium
citrate dose. His eGFR, as expected, progressively worsened and
at present is 0.67 mL/s/1.73 m2 (40 mL/min/1.73 m2) (at the age
of 20 years).
Urine calcium studies over time evolved as follows. Following
initiation of HCTZ, his UCa/Cr improved [range 0.84–1.4 mmol/
mmol (0.30 to 0.50 mg/mg)]. At the age of 12 years, 2 months
after his final HCTZ dose was established, his UCa/Cr continued
to be mildly elevated [range 0.84–1.52 mmol/mmol (0.3–0.54 mg/
mg)]. Ratios further improved after the addition of amiloride to
0.96 mmol/mmol (0.34 mg/mg) and then 0.67 mmol/mmol
(0.24 mg/mg). Oneyear after being onhis stableHCTZ and amilor-
ide doses, his UCa/Cr had normalized at 0.5 mmol/mmol
(0.18 mg/mg). During this time, timed urine collections were
not logistically possible due to his developmental delay and en-
uresis. The first 24-h urine collection that could be obtained
was at the age of 15 years. This has a urine volume of 2400 mL
with a creatinine excretion of 15 mg/kg/day. On this specimen,
his 24-h urine calcium excretion was normal at 137 mg (3.3 mg/
kg/day) with a urine sodium excretion of 151 mmol, a minimally
elevated urine oxalate excretion of 40 mg (or 57 mg/1.73 m2/day,
normal <55 mg/1.73 m2/day) and a citrate excretion that was ele-
vated at 1661 mg/g creatinine. His urinary supersaturation for
calcium oxalate was normal at 0.62 (mean 1.77), although his
brushite and hydroxyapatite supersaturations were elevated at
0.39 (mean 0.21) and 9.75 (mean 3.96), respectively. His urine
pH was high at 8.4, likely contributing to the elevated urinary
supersaturation. At last follow-up at the age of 20 years, his urin-
ary calcium excretion remains normal at 28 mg (0.53 mg/kg/day)
on a good 24-h collection (urinary creatinine excretion of 18 mg/
kg/day) and normal urinary supersaturation for calcium oxalate,
brushite and hydroxyapatite.
Discussion
Thiazide diuretics are a well-established treatment for hypercal-
ciuria in calcium stone formers and have been shown, in long-
term follow-up studied, to reduce the risk of recurrent stone
formation [7]. The mechanism of action of thiazides has been
extensively studied, both in animals and in humans. While
much of the attention related to these agents has focused on
their effects on distal tubular function, evidence from studies
suggests a more complex mechanism of action. At a tubular
level, it is hypothesized that by inducing mild volume depletion,
thiazides increase proximal tubular resorption of water, sodium
and calcium, thereby reducing urinary calcium excretion; this re-
duction in urinary calcium excretion has been demonstrated in
an animal model [8]. In addition to reducing urinary calcium,
thiazides have also been shown, by unclear mechanisms, to
reduce gastrointestinal absorption of calcium and phosphorus;
the net result of these is to promote a positive calcium balance
in the body [8, 9]. Similar effects on phosphate retention were
also noted in the same studies. Both of these effects lead to a
reduction in the urinary supersaturation for calcium phosphate,
as was seen in our patient. Inconsistent effects of thiazides on
urinary oxalate excretion have been noted. In the genetic hyper-
calciuric stone-forming rat model, an increase in urinary oxalate
excretion was seen and was presumed to be due to lower intes-
tinal calcium bioavailability to bind to dietary oxalate and pre-
vent it from being absorbed, since more of it would be bound to
phosphorus present in the intestinal lumen [8]. Other studies,
in humans treated with thiazides, have shown different results,
with some showing a reduction in urinary oxalate excretion
and others no change [10, 11]. Since our patient did not have a
baseline urinary oxalatemeasurement, due to his inability to col-
lect a timed urine specimen, whether he experienced a change in
his urinary oxalate excretion over time could not be ascertained.
However, it was reassuring that his urinary calcium oxalate
supersaturation was normal on HCTZ. Themechanism of hyper-
calciuria in patients with Lowe syndrome is related to the prox-
imal tubular dysfunction that is part of the underlying disease
process, leading to urinary calcium wasting.
In summary, our report demonstrates the safety and efficacy
of thiazide diuretics in reducing urinary calcium excretion and
stabilizing the stone burden in children with Lowe syndrome.
This occurred safely and in spite of an underlying tubulopathy,
which may indicate that the major site of action of these agents
was, at least in our patient, the gastrointestinal tract, as opposed
to the tubule. The use of thiazide diuretics can be associated
with hypokalemia and hyponatremia, to mention a few of their
side effects, and therefore, they should be used with caution.
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We feel that this case illustrates that thiazides, at least in low
doses, can be safely used (or at least attempted) even in the pres-
ence of a tubulopathy such as Fanconi’s syndrome, to reduce
urinary calcium excretion. Whether all children with Lowe syn-
drome (and others with Fanconi’s syndrome) who have hyper-
calciuria should receive a trial of thiazides to prevent stone
formation or not remains to be determined.
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